# PetVivo Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/PetVivo Holdings, Inc.). ## Overview PetVivo Holdings, Inc. is a U.S.-based animal health company focused on veterinary medical devices and therapeutics. Its core commercial product is Spryng®, which is sold to veterinarians and distributed through animal-health wholesalers and distribution partners. ## Products & services • Spryng® veterinary medical device • Veterinary distribution through wholesalers • Direct sales to veterinarians • Animal health product commercialization support - **Spryng® product sales** (100%) — Sales of the company's lead veterinary medical device used in animal care settings. - **Direct veterinary sales** (0%) — Sales made directly to veterinarians through the company's own sales efforts. - **Distributor sales** (0%) — Sales routed through animal-health distribution partners such as MWI, Covetrus, Vedco, and Clipper. - Spryng® veterinary medical device - Veterinary distribution through wholesalers - Direct sales to veterinarians - Animal health product commercialization support ## Customers PetVivo sells primarily into the veterinary market, where veterinarians buy Spryng® for use in animal treatment settings. A meaningful portion of sales also flows through animal-health distributors and wholesalers that serve veterinary clinics and practices. The business depends on both end-customer adoption by veterinarians and the ability of distribution partners to place product efficiently. - **Veterinarians** (primary) — Buy Spryng® directly for use in treating animal patients and for clinic inventory. - **Animal-health distributors** (primary) — Purchase and resell Spryng® to veterinary customers through established distribution networks. - **Veterinary clinics and practices** (secondary) — Use or stock the product as part of routine animal care and treatment workflows. - **Pet owners** (emerging) — Influence demand indirectly through willingness to pursue veterinarian-recommended treatments. - Veterinarians buying Spryng® for clinical use - Animal-health distributors placing product into clinics - Veterinary practices seeking non-surgical treatment options - Pet owners indirectly reached through veterinarian recommendations ## Geography PetVivo is headquartered in the United States and its commercial activity is centered on the U.S. veterinary market. The company’s reported distribution relationships and direct sales efforts are focused on U.S. veterinarians, making domestic adoption the key geography for revenue generation. No country-level revenue breakdown was disclosed in the provided excerpts. - Headquartered in the United States - Primary commercial market is U.S. veterinarians - Sales are supported by U.S. distribution partners - No country-level revenue disclosure in the excerpts ## Strategy PetVivo’s strategy is to expand commercialization of Spryng® through a mix of direct sales and third-party distribution. The company is also focused on building brand awareness and product promotion in the veterinary market to increase adoption and market penetration. - **Expand U.S. commercialization of Spryng®** (short-term) — Revenue growth depends on broader veterinarian adoption and stronger channel execution. - **Strengthen distribution relationships** (short-term) — Third-party distributors extend market reach and are important to product placement. - **Improve marketing and product promotion** (medium-term) — Awareness and promotion are necessary to drive veterinarian demand in a competitive market. - Expand Spryng® commercialization in the United States - Use both direct sales and distributor channels - Strengthen marketing and promotional reach - Build sales coverage and channel support - Increase product adoption among veterinarians ## Risks PetVivo faces execution risk because its business depends on building a sales force, managing distributors, and converting veterinarians into repeat customers. It also operates in a highly competitive animal-health market where larger companies have greater resources, and its small scale increases sensitivity to channel loss, brand weakness, and financing constraints. - **Dependence on Spryng® commercialization** [high] — The company’s revenue base is concentrated in a single lead product, so weak adoption would directly limit growth. - **Loss or disruption of distribution agreements** [high] — A large share of revenue is generated through distributors, so partner changes can quickly affect sales reach. - **Competition from larger animal-health companies** [medium] — Competitors have greater financial, technical, and commercial resources and established brands. - **Going-concern and financing risk** [critical] — The company has disclosed substantial doubt about its ability to continue as a going concern, making access to capital critical. - **Nasdaq delisting / OTCQB trading status** [high] — Loss of a senior exchange listing can reduce liquidity, investor access, and financing flexibility. - Dependence on Spryng® as the lead commercial product - Distributor concentration and partner termination risk - Competition from larger animal-health companies - Sales and marketing execution risk in a niche market - Going-concern and financing risk from limited resources ## Accounting PetVivo’s accounting is shaped by early-stage financing, equity issuances, and going-concern disclosures, which can materially affect dilution and capital structure analysis. Investors should also watch stock-based compensation, warrant exercises, and any valuation judgments tied to equity-linked instruments and service-based share issuances. - **Going-concern assessment** — Affects audit opinion, disclosure, and valuation assumptions - **Stock-based compensation** — Impacts operating expenses and share count - **Warrants and preferred stock conversions** — Affects equity, dilution, and potentially fair value measurements - **Non-cash consulting consideration** — Affects SG&A and equity balances - Going-concern disclosure affects liquidity and valuation analysis - Equity issuances and RSUs create dilution and compensation expense - Warrant exercises affect capital structure and cash proceeds - Consulting shares and non-cash settlements affect expense recognition - Early-stage estimates may be sensitive to fair value judgments --- *Last updated: 2026-04-29T04:48:28.072567+00:00*